Abstract
Highly active antiretroviral therapy (HAART) has markedly prolonged life expectancy in patients infected with the human immunodeficiency virus (HIV). Use of HAART has been associated with development of a metabolic syndrome that may increase the risk of developing ischemic heart disease. The purpose of this review is to discuss the incidence and clinical manifestations of the metabolic syndrome in patients with HIV infection and contributing factors, as well as whether cardiovascular risk is disproportionately elevated in patients with HIV-associated metabolic syndrome.
| Original language | English |
|---|---|
| Pages (from-to) | 79-82 |
| Number of pages | 4 |
| Journal | Journal of the cardiometabolic syndrome |
| Volume | 3 |
| Issue number | 2 |
| DOIs | |
| State | Published - 2008 |